MedPath

Clinical Study on Prodovite® VMP35 Supplement on Athletic Performance

Not Applicable
Conditions
Athletic Performance
Interventions
Dietary Supplement: Clinical Investigation on Enhanced Sports Nutrition and Performance Activities by Prodovite VMP35 Supplement
Dietary Supplement: Broad Spectrum Safety
Registration Number
NCT04121481
Lead Sponsor
Victory Nutrition International, Inc.
Brief Summary

This pilot investigation will conduct a randomized placebo-controlled, double-blind study in 150 volunteers (age: 18-74 years) over a period of 90 consecutive days. A statistician will be involved in this project. Body weight, body mass index (BMI), waist circumference, blood chemistry, blood pressure and heart rate, body and hand grip strength, speed and endurance studies including open circuit spirometry-based assessment of pulmonary function will be assessed. Other parameters to be evaluated include oxygen consumption, CO2 production and metabolic parameters, VO2 max, respiratory exchange ratio (RER), anaerobic threshold, ventilatory equivalents for oxygen (VE/V02) and exhaled carbon dioxide (VE/VC02)2,3. Subjects will participate in completed maximal graded exercise tests (GXT) on a treadmill or in set distance open-field sprints using open-circuit spirometry. Lower and Upper Body Strength will be evaluated. E-Diary will be provided to all participants. Survey Monkey program will be provided to all subjects and regularly updated by all study participants daily and endorsed by the co-Principal Investigator.

Detailed Description

A novel patented Prodovite® VMP35 Multi-Nutrient-Complex (MNC), a vitamin, mineral, and phytonutrient encapsulated liquid formulation, was prepared using a novel proprietary SK713 SLP multi-lamellar clustoidal non-GMO phospholipid Prodosome nutrient absorption/delivery technology in a state-of-the-art multistep cGMP and NSF-certified manufacturing facility. This developmental technology is biodegradable and biocompatible. Preliminary study in our laboratory demonstrated the efficacy of Prodovite® VMP35 in Sports Nutrition. We hypothesize that Prodovite® VMP35 supplement will enhance athletic performance, lean-body muscle mass, increase exercise tolerance, and improve anabolic parameters in healthy human subjects. The aim of this pilot study is to evaluate the effect of oral supplementation of Prodovite® VMP35 on exercise endurance, muscle strength, anabolic parameters and lean body mass in healthy human subjects. We hypothesize that Prodovite® VMP35 supplementation will enhance and increase exercise performance, tolerance, lean-body muscle mass, improve anabolic parameters and blood chemistry parameters in healthy human subjects. Accordingly, 150 healthy male and female subjects will be randomly assigned to receive either Prodovite® VMP35 or placebo in the form of single dose sealed containers for 90 consecutive days and muscle strength, endurance, speed, anabolic/catabolic parameters and muscle mass will be evaluated by dual energy X-ray absorptiometry (DEXA), hand-grip strength test, cycle ergometer test, spirometer assessment and assay of Blood chemistry and serum biomarkers will be evaluated before and after intervention.

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
150
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
PlaceboClinical Investigation on Enhanced Sports Nutrition and Performance Activities by Prodovite VMP35 SupplementApproximately a total of 75 participants will be assigned in the Placebo Group (two divided doses will be given)
Treatment GroupClinical Investigation on Enhanced Sports Nutrition and Performance Activities by Prodovite VMP35 SupplementApproximately a total of 75 participants will be assigned in the Treatment Group (two divided doses will be given) Adverse Event Monitoring will be Strictly Enforced
Treatment GroupBroad Spectrum SafetyApproximately a total of 75 participants will be assigned in the Treatment Group (two divided doses will be given) Adverse Event Monitoring will be Strictly Enforced
PlaceboBroad Spectrum SafetyApproximately a total of 75 participants will be assigned in the Placebo Group (two divided doses will be given)
Primary Outcome Measures
NameTimeMethod
Anthropometric Measurements: Waist-Hip RatioOver a Period of 90-Consecutive Days

Waist : Hip Ratio

Anthropometric Measurements: Body WeightOver a Period of 90-Consecutive Days

Body Weight (Kilograms)

Anthropometric Measurements: Blood Pressure (mmHg)Over a Period of 90-Consecutive Days

Blood Pressure (mmHg)

Body Composition and Bone Mineral Density: DEXA (GE)Over a Period of 90-Consecutive Days

DEXA and Bone Mineral Density

Ergometric Assessment: TreadmillOver a Period of 90-Consecutive Days

Ergometric measurements

Handgrip DynamometerOver a Period of 90-Consecutive Days

Handgrip strength

Respiration Quality and Rate: SpirometerOver a Period of 90-Consecutive Days

Respiration Quality, VO2 and VCO2 assessments

Endurance StudiesOver a Period of 90 Consecutive Days

Cycle Ergometer, Bench Press and Leg Press

Anthropometric Measurements: HeightOver a Period of 90-Consecutive Days

Height (Meters)

Anthropometric Measurements: Waist CircumferenceOver a Period of 90-Consecutive Days

Waist Circumference (Meters)

Secondary Outcome Measures
NameTimeMethod
Lipid ProfileOver a Period of 90-Consecutive Days

Complete Lipid Profile

Total Blood ChemistryOver a Period of 90-Consecutive Days

Blood Chemistry

Trial Locations

Locations (1)

Champions Sports Performance & Hardcore Serious Fitness

🇺🇸

Cornelius, North Carolina, United States

© Copyright 2025. All Rights Reserved by MedPath